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resumo
A terapia fotodinâmica (TFD) é um promissor tratamento clínico que emprega a combinação de luz visível, 
oxigênio e uma substância fotossensibilizadora para tratar doenças de caráter oncológico. Esse tipo de 
tratamento induz a morte celular programada (apoptose) em tecido tumoral. No entanto, o mecanismo de 
indução de apoptose por TFD não está bem caracterizado. Muitos fotossensibilizadores possuem como alvo 
principal a mitocôndria. O tratamento com TFD causa danos nessa organela e induz a apoptose através da 
liberação de citocromo c, fator de indução de apoptose, Smac/DIABLO e certas pró-caspases. A liberação 
dessas proteínas, a partir da mitocôndria, é regulada por uma família de proteínas pró e antiapoptóticas, 
conhecida como família BCL-2. A proposta dessa minirrevisão é apresentar algumas publicações recentes 
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These proteins are cytochrome c (cyt c)(21), apoptosis 
inducing factor (AIF)(28), and Smac/DIABLO(6), which 
initiate downstream apoptotic signaling events.
Apoptosis
Programmed cell death (PCD) or apoptosis is a 
fundamental property of all multicellular organisms. 
The PCD, a gene-regulated form of cell death, occurs at 
different stages of growth, for example, to eliminate cells 
between developing digits or degeneration of neurons 
In photodynamic therapy (PDT), visible light 
activates a photosensitizing drug accumulated in 
tumor or other abnormal tissue(10, 13, 25). The interaction 
between the excited photosensitizer and molecular 
oxygen produces singlet oxygen (1O2) as well as other 
reactive oxygen species (ROS) to induce cancer cell 
death(2, 24, 42, 44, 49). The mode of cell death by PDT is 
often apoptosis, and substantial evidence supports 
the involvement of mitochondria in this process(32, 
65-67). During apoptosis, mitochondria release soluble 
proteins from the intermembrane space into cytosol. 
 abstract
Photodynamic therapy (PDT), a promising cancer treatment that employs a combination of a photosensitizing 
chemical, oxygen, and visible light, induces apoptosis in tumor cells. However, the precise mechanism of 
PDT-induced apoptosis is not well characterized. Many of the photosensitizers currently in clinical or pre-
clinical studies of PDT are localized in or have a major influence on mitochondria. The treatment with PDT 
causes mitochondrial damage and induces apoptosis through the release of cytochrome c (cyt c), apoptosis-
inducing factor (AIF), Smac/DIABLO and certain procaspases. Proapoptotic and antiapoptotic members of 
BcL-2 family regulate the release of these proteins from mitochondria. The purpose of this mini-review is to 
present some recent publications that focus on the involvement of the mitochondria in apoptosis of cancer 






that fail to form proper cellular connections. Some cells also 
die during the organism’s life cycle to regulate the size of 
the cell population in tissues. Additionally, when cells are 
confronted with environmental stresses, they can either be 
destroyed accidentally or can self-destruct using an active 
mechanism (apoptosis). This depends on the stress type or 
intensity(8). Disturbed PCD plays a major role in diseases, 
such as cancer and neurodegeneration(50). Excessive PCD 
can lead to degenerative diseases(56), whereas insufficient 
apoptosis can lead to cancer(18), because the organism loses 
control of the proliferation of a cell line(20).
Morphology of apoptosis
The hallmarks of apoptosis in animal cells include 
chromatin condensation, internucleosomal DNA cleavage, 
cell fragmentation, and formation of apoptotic bodies. These 
bodies are removed by scavenging macrophages(17).
DNA fragmentation in particular has been used as an 
indication of apoptosis, and several simple assays have 
been used to assess the extent of DNA fragmentation in 
apoptotic cells. For example, agarose gel electrophoresis(47) 
is used to demonstrate the ladder patern of DNA wich is 
generated by endonucleolytic cleavage of genomic DNA 
into nucleosomalsize DNA of approximately 180 bases long 
(monomers) or oligonucleotides, which are multiples of 180 
bases (oligomers)(69).
Mitochondrial apoptotic pathway
Mitochondria have emerged as the central processing 
organelles in the majority of apoptotic pathways. Signals 
from cell surface death receptors or from damaged sites 
converge on mitochondria, leading to permeabilization 
of both mitochondrial membranes, dissipation of the 
inner membrane transmembrane potential and release 
of several apoptosis-related proteins, normally located in 
the intermembrane space of mitochondria(34, 35, 53). Some 
of these proteins are AIF, Smac/DIABLO, cyt c, and certain 
procaspases. The release of apoptosis-related proteins and 
collapse of the mitochondrial transmembrane potential results 
from the opening of a large conductance channel known as 
the permeability transition pore complex (PTPC), which 
forms at contact sites of the outer and inner mitochondrial 
membranes(46). This pore is formed by the transient complex 
of the voltage-dependent anion channel (VDAC) on outer 
membrane, the adenine nucleotide transporter (ANT) from 
the inner membrane and cyclophilin D in the matrix. The 
inner membrane is normally impermeable to anions, but 
when the PTPC pore forms, it is thought that the rapid 
movement of water causes this compartment to swell, 
rupturing the outer membrane(27, 28, 62).
AIF is localized in the mitochondria and released in 
response to PCD stimuli(28). This apoptosis-inducing factor 
moves directly to the nucleus, where it produces chromatin 
condensation and nuclear fragmentation(62).
Smac/DIABLO is a recently identified novel proapoptotic 
molecule, which is released from mitochondria into cytosol 
during apoptosis. This mitochondrial protein performs a 
critical function in apoptosis by eliminating the inhibitory 
effects of IAPs (inhibitor of apoptosis proteins)(6). The IAPs 
potently inhibit the catalytic activity of caspases(58).
In apoptotic cells the cyt c, a component of the electron 
transport chain that shuttles electrons between complexes III 
and IV (cytochrome oxidase), is released from mitochondria 
into cytosol, and interacts with Apaf-1 and pro-caspase 9 
to form a complex (apoptosome)(71). This complex causes 
a caspase activation cascade that culminates in cell death 
characterized by apoptotic morphology(39, 41,73, 74).
The cyt c release in apoptotic cells is regulated by BCL-
2 family proteins. The first apoptotic gene (BCL-2) was 
discovered at the beginning of the nineties and was shown 
to be a supressor of apoptosis(26). Other genes of the BCL-2 
family were subsequently found on the basis of sequence 
similarities and physical interactions. This gene family is now 
composed of proapoptotic and antiapoptotic members(52). 
Antiapoptotic members of this family, including BCL-2 and 
BCL-XL, bind to the mitochondrial outer membrane and 
block AIF(64), smac/DIABLO(1, 63), and cyt c efflux(3).
The proapoptotic members of the BCL-2 family, such as 
Bax and Bid, promote the release of cyt c and other proteins 
of the mitochondrial intermembrane space(3). Bax functions 
directly on mitochondria to stimulate the release of cyt 
c by forming a selective pore in the outer mitochondrial 
membrane, whereas others argue that Bax interacts 
with VDAC and/or ANT to facilitate opening PTPC(14, 29, 
57). Evidence indicates that Bid induces conformational 
change in Bax that allows this protein to insert in the outer 
mitochondrial membrane and stimulate cyt c release(15).
The hydrolytic reactions of apoptosis are catalyzed by a 
family of proteases now termed caspases. The caspases are 
cysteine proteases (with cysteine in their active center) present 
in cytosol and activated by mitochondrial proteins released 
into cytosol, for example cyt c. These proteases activate other 
procaspases in a sequential cascade and are also activated 
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by self-cleavage(46, 62). Caspases are often classified as initiator 
(caspases 2, 8, 9, 10), and effector (caspases 3, 6, 7). Initiator 
caspases, such as caspase 8, activate effector caspases which 
in turn cleave and inactivate proteins that protect living 
cells from apoptosis, such as the DNA repair protein, poly 
(ADP-ribose) polymerase (PARP), ICAD/DFF45 (inhibitor 
of caspase-activated DNase, the nuclease responsible for 
DNA fragmentation), and antiapoptotic BCL-2 proteins. 
Other actions of caspases in apoptosis include cleavage of 
cytoskeletal proteins, including the lamins, proteins forming 
the nuclear lamina; cytoplasmic intermediate filaments, and 
several proteins involved in cytoskeletal regulation. This 
cleavage provokes disassembly of cell structures that depend 
on the cytoskeleton(46).
Figure 1 demonstrates a summary of the apoptotic 
mechanism mediated by mitochondria:
Photodynamic therapy
Photodynamic therapy is considered to have its origins 
in 1900 with the classic experiments by Raab. He observed 
that when paramecia were exposed to either sunlight 
alone or to the chemical acridine in the dark, no effects 
were observed. However, a lethal reaction occurred if the 
microorganisms were exposed to an acridine solution and 
sunlight concurrently. He described this toxic effect as dose 
dependent, with respect to both acridine concentration and 
duration of exposure to sunlight(68).
Currently PDT is a clinical treatment that employs a 
combination of a photosensitizing compound, oxygen, 
and visible light for the therapy of several oncological, 
cardiovascular, dermatological, and ophthalmic diseases(38). 
Figure 1 – Schematic representation of the programmed cell death (apoptosis) 
mediated by mitochondria. Mitochondrial ROS production, PTPC formation, and 
swelling provoke release of proapoptotic proteins (cyt c, AIF, and Smac/DIABLO) 
into cytosol. These proteins provoke caspase activation resulting in PARP and lamin 
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This technique is characterized by systemic administration 
of a photosensitizing drug, which is preferentially retained 
by diseased tissue. The photodestruction of the tumor is 
performed after visible light incidence(5, 45). The treatment 
results in the production of ROS, such as 1O2 and superoxide 
radical (O2
•-), that provoke a sequence of oxidative events 
resulting in cancer cell death by apoptosis and/or necrosis(16, 
31) and eventual tumor ablation (Figure 2)(5).
The ROS, generated in PDT, damage biomolecules, 
such as proteins and lipids, generating photoproducts. 
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The mechanisms of ROS production can be type I, type 
II or both. The superoxide and other radicals species are 
generated with the type I mechanism by electron transfer 
from photosensitizer, in the excited triplet state (T1), to 
ground-state oxygen (3O2). Singlet oxygen is generated 
with the type II mechanism by energy transfer from 
phtotosensitizer T1 to 
3O2
(19, 59) (Figure 3).
At present, only one phototherapeutic agent, namely 
Photofrin®, has been approved for clinical use in cancer 
treatment(11). This drug has been approved in Canada for the 
prophylactic treatment of bladder cancer. The Netherlands, 
France, Germany, and Japan have approved it in cases 
of early and advanced stages of cancer of the lung, the 
digestive tract, and the genitourinary tract(9). In the United 
States of America, Photofrin® is the only photosensitizer 
approved by FDA (Food and Drug Administration) for 
clinical use in patients with esophageal and lung cancer(37, 
48). However Photofrin® suffers from some drawbacks(12). 
Firstly, it is a complex mixture of several partially unidentified 
porphyrins and it shows a poor selectivity in terms of target 
tissue/healthy tissue ratios. Secondly, its low extinction 
coefficients require the administration of relatively large 
amounts to obtain a satisfactory phototherapeutic response. 
Furthermore, it presents a high accumulation rate in skin, 
wich induces a prolonged cutaneous light ultrasensibility 
lasting for up to 6-8 weeks after PDT treatment. During this 
post-treatment period, patients have to stay out of sunlight 
to avoid a severe sunburn reaction(51).
The problems encountered with Photofrin® have 
encouraged the development and the study of alternative 
photosensitizers, such as Hypericin, Foscan, NPe6, Lutecium 
Texaphyrin, Phtalocyanine Pc 4, and others(46, 55, 61).
Mitochondrial apoptotic pathway  
in photodynamic therapy
Many of the photosensitizers currently in clinical or 
pre-clinical studies of PDT are localized in or have a major 
Figure 3 – Mechanisms (types I and II) of ROS generation by combination of light, 
photosensitizer (P), and ground-state oxygen (3O2). Ground-state photosensitizer 
(S0) is irradiated with visible light generating excited singlet state photosensitizer (S1). 
S1 can relax back to excited state photosensitizer (T1) generating superoxide radical 
(3O2
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Figure 4 – Reaction of singlet oxygen with tryptophan
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influence on mitochondria, and PDT is a strong inducer of 
apoptosis in many situations(46). There are many similarities 
between the mechanisms by which mitochondria regulate 
apoptosis and mechanisms by which PDT kills cancer 
cells. During PDT, 1O2 attacks mitochondrial proteins 
and possibly alters their amino acid structures (Figure 4), 
thereby disrupting the proteins folding conformation. This 
may force them into other conformations that disrupt their 
normal functioning(43).
Treatment with antioxidant inhibits cyt c release, 
caspase 3 activation and PARP cleavage associated with 
PDT thereby supporting the contention that ROS generated 
by PDT induces apoptosis in cancer cells(40). It has been 
demonstrated also that 1O2, generated by irradiation of 
rose bengal with visible light, induces apoptosis in human 
promyelocytic leukemia HL-60 cells(72). The PDT-treatment 
using rose bengal as the photosensitizer induces also 
apoptosis in human epidermal carcinoma A431 cells, but 
this event can be inhibited by 1O2 scavengers and specific 
caspase inhibitors(7). The antiapoptotic protein BCL-2 is one 
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target of PDT, and PDT damage to BCL-2 contributes to 
efficient induction of apoptosis(70). It has been observed that 
PDT utilizing photosensitizer phtalocianine-4 (Pc-4) causes 
photodestruction of BcL-2 in mitochondria. This event 
induces apoptosis in cancer cells but it can be prevented 
by singlet oxygen scavenger L-histidine. In this work 
photochemical damage was not observed in proapoptotic 
protein Bax, the VDAC, or the ANT (components of PTPC 
in mitochondria)(70).
Formation of mitochondrial reactive oxygen species 
was detected within minutes when human epidermal 
carcinoma A431 cells were exposed to Pc 4 and 670-
675nm light. This was followed by mitochondrial inner 
membrane permeabilization, depolarization, swelling, 
and cyt c release to cytosol, resulting in apoptotic cell 
death(36). The irradiation of murine leukemia L1210 cells 
in presence of three photosensitizers (CPO, SnET2, and 
m-THPC), caused rapid decrease of the mitochondrial 
membrane potential, release of cyt c into cytosol and 
activation of caspase-3. These effects were followed by the 
appearance of an apoptotic morphology. In this treatment 
BcL-2 photodamage was detected directly after irradiation 
but the proapoptotic protein Bax is not affected(30). 
Apoptosis was also induced in smooth muscle cells by the 
combination of the photosensitizer verteporfin and visible 
light. After PDT, an increase in mitochondrial cyt c and AIF 
levels were detected in the cytosol. AIF translocated from 
mitochondria to the nucleus during the progression of 
apoptosis. In addition, cyt c release provoked activation 
of multiple caspases during PDT(22). Cleavage of PARP and 
DNA fragmentation were observed in tumor cells treated 
with the photosensitizer Hypericin. These events were 
preceded by cyt c release, activation of initiator caspase-8, 
9, 3, and Apaf-1(4).
PDT protocols employing lysosomal sensitizers induce 
apoptosis via a mechanism that causes cyt c release prior 
to loss of mitochondrial membrane potential. It was 
demonstrated that lysosomal photodamage initiates 
mitochondrial-mediated apoptosis in murine hepatoma 
1c1c7 cells. In this work, fluorescence microscopy 
demonstrated that the photosensitizer Npe6 was localized 
in the lysosomes. Irradiation of cells with Npe6 induced 
rapid destruction of lysosomes, and subsequent cleavage/
activation of proapoptotic Bid, pro-caspase-9 and 3. 
This activation was provoked by release proteases from 
lysosomes. The activation of Bid caused the decrease of 
mitochondrial membrane potential and cyt c release. This 
work demonstrated that photodamaged lysosomes trigger 
the mitochondrial apoptotic pathway by releasing proteases 
that activate Bid(54).
Photodynamic therapy using photosensitizer Pc-4 
causes mitochondrial damage and induces apoptosis 
through the release of cyt c to the cytosol. Another protein 
situated in the mitochondrial intermembrane space, 
Smac/DIABLO, is also released to the cytosol in response 
to apoptotic stimuli and promotes caspase activation 
by binding IAP(67). Recently, a study was made of the 
mechanism of cytotoxic effects of 5-aminolevulinic acid-
based photodynamic therapy (ALA-PDT) on the human 
promyelocytic leukemia cell line HL60. The decrease of 
mitochondrial membrane potential was accompanied by a 
decrease in the ATP level, release of cyt c into cytosol, the 
activation of caspases 9 and 3, and the cleavage of PARP 
followed by DNA fragmentation. These data suggest that 
ALA-PDT activates the mitochondrial apoptotic pathway 
in cancer cells(23).
In the screening of the new anticancer agents for use in 
PDT, it was discovered that a methanol extract of bamboo 
leaves induced rapid apoptosis in the human leukemia CMK-
7 cell line. This apoptosis was evaluated by monitoring the 
caspase 3 activation and DNA cleavage(33). ATX-S10 (Na), 
a novel hydrophilic chlorin photosensitizer, shows good 
accumulation in tumors and is suitable for use in PDT. 
Recently, the mechanism of PDT-induced death using ATX-
S10 (Na) and diode laser in normal human keratinocytes 
(NHK) was investigated. ATX-S10 (Na)-PDT had induced 
apoptosis of NHK in two hours and the maximal effect was 
observed after six hours following irradiation. The effect 
was supressed by pretreatment of NHK with inhibitors 
of caspases 3, 6, 8 and 9, and western blotting revealed 
cytosolic release of cyt c and AIF(65).
Conclusion
The importance of mitochondria as targets for the 
initiation of apoptosis by PDT has been demonstrated by 
several investigators. They found that many photosensitizers 
that bound to mitochondria induced apoptosis upon 
photoirradiation. In this treatment the irradiation with 
visible light results in the generation of large amounts of 
ROS which result in mitochondrial damage, PTPC formation 
and release of proapoptotic proteins into cytosol. These 
proteins cause the activation of caspases, resulting in DNA 
fragmentation and, finally, lead to death of tumor tissue by 
apoptosis (Figure 5).
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